Jeffrey Andolina
Concepts (37)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Anthracyclines | 1 | 2010 | 7 |
Why?
|
Thinness | 1 | 2010 | 12 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2010 | 35 |
Why?
|
Core Binding Factors | 1 | 2009 | 1 |
Why?
|
Phosphotransferases | 1 | 2009 | 24 |
Why?
|
Myelodysplastic Syndromes | 1 | 2011 | 27 |
Why?
|
Survivors | 1 | 2010 | 45 |
Why?
|
Heart Diseases | 1 | 2010 | 92 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2011 | 49 |
Why?
|
Heart | 1 | 2010 | 88 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2009 | 53 |
Why?
|
Neoplasms | 1 | 2010 | 239 |
Why?
|
Infant | 2 | 2010 | 464 |
Why?
|
Retrospective Studies | 2 | 2010 | 656 |
Why?
|
Child, Preschool | 2 | 2010 | 555 |
Why?
|
Cytogenetics | 1 | 2011 | 13 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2011 | 21 |
Why?
|
Transplantation Conditioning | 1 | 2011 | 23 |
Why?
|
Heart Function Tests | 1 | 2010 | 14 |
Why?
|
Disease-Free Survival | 1 | 2011 | 102 |
Why?
|
Radiotherapy Dosage | 1 | 2010 | 55 |
Why?
|
Risk | 1 | 2011 | 203 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 94 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 8 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2009 | 13 |
Why?
|
Echocardiography | 1 | 2010 | 93 |
Why?
|
Stem Cell Transplantation | 1 | 2010 | 50 |
Why?
|
Proto-Oncogene Proteins | 1 | 2009 | 113 |
Why?
|
Pediatrics | 1 | 2011 | 133 |
Why?
|
Time Factors | 1 | 2011 | 896 |
Why?
|
Transcription Factors | 1 | 2009 | 201 |
Why?
|
Treatment Outcome | 1 | 2011 | 662 |
Why?
|
Humans | 3 | 2009 | 1858 |
Why?
|
Male | 2 | 2010 | 1558 |
Why?
|
Female | 2 | 2010 | 1646 |
Why?
|
Child | 1 | 2011 | 750 |
Why?
|
Adolescent | 1 | 2011 | 892 |
Why?
|
